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ABSTRACT
www.scielo.br/jaos
Objective: To detect the presence and concentration of methylparaben in cartridges of commercial Brazilian local anesthetics. Material and methods: Twelve commercial brands 
(4 in glass and 8 in plastic cartridges) of local anesthetic solutions for use in dentistry 
were purchased from the Brazilian market and analyzed. Different lots of the commercial 
brands were obtained in different Brazilian cities (Piracicaba, Campinas and São Paulo). 
Separation was performed using high performance liquid chromatography (HPLC) with UV-
Vis detector. The mobile phase used was acetonitrile:water (75:25 - v/v), pH 4.5, adjusted 
	
	-1. Results: When detected in the solutions, the 
methylparaben concentration ranged from 0.01% (m/v) to 0.16% (m/v). One glass and all 
plastic cartridges presented methylparaben. Conclusion: 1. Methylparaben concentration 
varied among solutions from different manufacturers, and it was not indicated in the drug 
package inserts; 2. Since the presence of methylparaben in dental anesthetics is not 
regulated by the Brazilian National Health Surveillance Agency (ANVISA) and this substance 
could cause allergic reactions, it is important to alert dentists about its possible presence.
Key words: Hypersensitivity.  Allergy. Local anesthetics.
INTRODUCTION
Local anesthesia continues to be the most used 
pain control method in dentistry. The knowledge 
of pharmacology and toxicity properties provides 
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agents16. In Brazil around 250 million anesthetic 
cartridges are used per year. The low incidence of 
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the great clinical safety of these formulations when 
correctly used17.
In 1904, Einhorn synthesized a new ester 
anesthetic, procaine, which would replace cocaine 
and avoid the risk of drug addiction3. However, the 
esters showed a high incidence of allergic reactions 
caused by their metabolite, the para-aminobenzoic 
acid (PABA), which results from esters’ hydrolysis in 
plasma6. A new chemical group of anesthetics – the 
amides – appeared with the discovery of lidocaine 
in the 1940s, improving the safety of pain control 
in dentistry14.
The anesthetics of the amide group successfully 
replaced the ester anesthetics, which were 
gradually discarded due to their allergenic potential. 
In Brazil, ester anesthetics (benzocaine) are used 
only for topical anesthesia in dentistry. All the 
local anesthetic solutions, which are available in 
the injectable form today, belong to the amide 
group and rarely cause allergic reactions. Cases of 
allergy have been related due to the preservatives 
or antioxidants added to the solutions13.
The dental anesthetic solutions usually contain 
an anesthetic (chloride salt) either associated 
with vasoconstrictors or not, dissolved in a vehicle 
(sterile water). Antioxidants, mainly sodium or 
potassium bisulphite, are added to solutions 
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containing sympathomimetic vasoconstrictors9. 
These antioxidants are used to assure a reasonable 
concentration of sympathomimetic amines in 
the anesthetic solutions. Sodium bisulphite, for 
example, is used in concentrations from 0.05% 
to 0.1%14. These antioxidants act as “suicide 
components” and delay the vasoconstrictors’ 
oxidation. The sulphites react more quickly 
with oxygen and other catalysts, protecting the 
vasoconstrictors8. However, the antioxidants can 
cause allergic reactions, which have been related 
in the literature2.
Another component added to many Brazilian 
anesthetic solutions is methylparaben, which is 
also used in cosmetics and food products. The 
main function of this substance is to act as a 
bacteriostatic agent and to maintain the sterility 
of the anesthetic solution13.
Similarly to ester anesthetics, methylparaben 
also produces PABA as a metabolite, which is a 
highly allergenic substance related to various cases 
of hypersensitivity4. Due to this characteristic, the 
use of methylparaben in dental cartridges was 
prohibited in the United States by the regulatory 
agency - Food and Drug Administration (FDA) - in 
the mid-1980s9. In Brazil, the regulatory agency – 
the Brazilian National Health Surveillance Agency 
(ANVISA) - has not yet adopted a standardization 
considering the presence of bacteriostatic agents 
in dental local anesthetic solutions.
Sample Commercial 
Brand
Anesthetic 
Composition
Cartridge 
Material
Percentage of 
methylparaben
CV (%)1 Described 
in drug 
package 
insert?
Concentration 
informed?
1 Lidostesina 
100®
	
 
1:100,000 
epinephrine
Plastic 0.01 0.77 Yes No
2 Lidostesina 
50®
	
 
1:50,000 
epinephrine
Plastic 0.01 0.66 Yes No
3 Lidostesin 
®
	
 
1:50,000 
norepinephrine
Plastic 0.01 4.36 Yes No
4 Mepivalem 
®

	
 Plastic 0.01 3.96 Yes No
5 Citanest® 	
 
0.03 UI felypressin
Plastic 0.01 3.79 Yes No
6 Novocol® 	
 
1:2,500 
phenylephrine
Plastic 0.11 1.45 No No
7 Cirucaina® 
	
 
1:100,000 
epinephrine
Plastic 0.01 0.44 Yes Yes
8 Alphacaine® 	
 
1:100,000 
epinephrine
Glass  (-) No No
9 Articaine® 
	
 
1:100,000 
epinephrine
Glass  (-) No No
10 Prilonest® 	
 
0.03 UI felypressin
Glass 0.16 2.06 Yes No
11 Scandicaine 
®

	
 
1:100,000 
norepinephrine
Glass  (-) No No
12 Citocaina® 	
 
0.03 UI felypressin
Plastic 0.07 7.88 Yes No
Figure 1- Concentration of methylparaben in different cartridges available on the Brazilian market
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The aim of this study was to analyze the presence 
and the concentration of the methylparaben in local 
dental anesthetic solutions commercially available 
in Brazil. Furthermore, the drug package inserts 
were analyzed regarding the description of the 
presence of methylparaben in the solution.
MATERIAL AND METHODS
Twelve commercial brands of local anesthetic 
solutions commonly used in dentistry, purchased 
from the Brazilian market, were analyzed. Figure 1 
shows the characteristics of the solutions used in the 
study. Four local anesthetic brands were disposable 
in glass cartridges (G) and eight in plastic cartridges 
(P). Different lots of the commercial brands were 
bought in three different Brazilian cities (Piracicaba, 
Campinas and São Paulo).
To quantify methylparaben, a standard stock 
solution of 100 mg.L-1 of methylparaben (Sigma-
Aldrich, Milwaukee, WI, USA) in deionized water was 
used. From this solution, standard working solutions 
of 1, 5, 10, 15, 20, 25 mg.L-1 were prepared to 
establish an analytical curve.
HPLC grade acetonitrile (Mallinckrodt, Rio de 
Janeiro, RJ, Brazil), Milli-Q water (Millipore, Bedford, 
MA, USA) and acetic acid (Merck, Rio de Janeiro, 
RJ, Brazil) were used to prepare the mobile phase. 
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	
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Chromatographic separation was performed by 
using a Waters liquid chromatograph, consisting 
of a high pressure pump, model 510, Rheodyne 
injector, model 7125, UV-Vis detector, model 486. 
The mobile phase used was acetonitrile:water 
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>-1. A NovaPak (Waters, 
Milford, MA, USA) C8 column (150 mm x 3.9 mm 
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injections were performed in triplicate.
Data acquisition and analysis were performed 
by the software ChromPerfect for Windows, version 
3.52, and Report Write Plus (Justice Innovations, 
XY	*ZK*[\K'?	]
(LQ) of the instrument was determined from the 
analytical curve equation, QL=10s/S, being “s” the 
standard deviation of the regression equation and 
_\`			18.
RESULTS
Methylparaben was found in 9 of the 12 brands 
studied, in concentrations ranging from 0.01% 
to 0.16% (m/v), as shown in Figure 1. All the 
anesthetic solutions disposable in plastic cartridges 
presented methylparaben in their composition. One 
brand disposable in glass cartridges presented the 
compound. A chromatogram of one of the samples 
of the local anesthetic is shown in Figure 2.
The presence of methylparaben was mentioned 
in 9 anesthetic package inserts (Figure 1) and none 
of them reported its concentration.
DISCUSSION
Methylparaben is commonly used as preservative 
in many cosmetic and pharmaceutical products, 
and also in some food. It has been shown to be an 
effective antimicrobial agent, and it is used primarily 
as a bacteriostatic agent to maintain the sterility of 
some dental anesthetic solutions13.
Parabens are allowed as preservatives in foods 
and the maximum daily ingestion for human has 
been estimated as 4 to 6 mg/kg. In cosmetics, 
parabens are allowed in concentrations up to 1%7.
Some studies have reported that methylparaben 
has rarely been associated with immediate 
hypersensitivity, even after parenteral exposure. 
However, Macy, et al.12 (2002) related cases of 
patients with severe allergic reactions caused by 
methylparaben, with an approximate incidence of 
2%. Those authors also established methylparaben 
as the unique cause of the immediate hypersensitivity 
reaction, which was confirmed by cutaneous 
tests. Kajimoto, et al.10 (1995) related the 
occurrence of erythematous reactions in patients 
after the administration of prilocaine containing 
methylparaben.
According to Soni, et al.21 (2005), subcutaneous 
administration of methylparaben can also cause 
temporary fatigue, ataxy and respiratory depression 
at doses higher than 165 mg/kg in rats. Mason, 
et al.15 (1971) reported that the administration of 
methylparaben caused mammary adenocarcinoma 
in rats. In 1988, Routledge, et al.19 reported the 
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Figure 2- Chromatogram of one sample of local 
anesthetic for dentistry. Chromatographic conditions: 

	
 ! " #$% &% ' 
*
.min-1%+
/
;<=	%*>?K	
!
nm
SILVA GHR, BOTTOLI CBG, GROPPO FC, VOLPATO MC, RANALI J, RAMACCIATO JC, MOTTA RHL
J Appl Oral Sci. 447
and suggested that the safety of these substances 
should be reassessed, particularly in relation to 
the systemic exposure in humans. Tavares, et al.22 
(2009) related possible adverse effects of parabens 
in male fertility. Moreover, at present, some studies 
have shown the presence of methylparaben 
in breast tumors, suggesting the possibility of 
methylparaben having carcinogenic potential5.
The use of methylparaben in dental anesthetic 
cartridges was prohibited in the United States in 
198413. However, in Brazil this substance is still 
widely used in dental anesthetic cartridges. There 
is no data regarding the quantity of methylparaben 
in the solutions marketed in Brazil until now. 
Furthermore, manufacturers do not mention 
the concentration of this component in the drug 
insert package of their products. All anesthetic 
solutions contained in plastic cartridges evaluated 
in the present study showed methylparaben 
			]	
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and precision) of the proposed HPLC method. The 
main alleged reason for using methylparaben in 
the solutions contained in plastic cartridges is 
related to the chemical conservation and sterility 
of the anesthetic solution. The permeability of 
the plastic could result in oxygen infiltration 
inside the cartridge, demanding high quantities of 
preservatives. Another consequence of the plastic 
permeability is the mandatory use of some kind 
of bacteriostatic agent, such as methylparaben16.
The use of the glass cartridges is justified 
by the glass characteristics, since it is more 
hygienic, inert and impermeable. The hygiene of 
the glass containers is due its manufacturing from 
natural elements, which protect the products for 
a longer time and dispense the use of additional 
preservatives. In addition, it meets all the 
requirements demanded for storing liquids and 
foods for human consumption. Glass containers 
do not react with the product either, resulting in 
the preservation of taste, odor, color and quality. 
The absence of pores works as a barrier against 
any external agent, preserving and increasing the 
product useful life10,20.
Besides the necessary addition of methylparaben, 
the mechanical aspect of plastic cartridges must 
be also considered. The rubber-plunger slide is 
smoother in glass than in plastic cartridges and 
a higher friction between the plunger and the 
cartridge walls could interfere with the anesthetic 
injection. The force used on the syringe plunger is 
more variable when plastic cartridges are used, and 
					
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aspiration can be better observed through the 
transparent walls of the glass cartridges16.
In addition, dental anesthetics containers must 
be disposable and used only once, differing from 
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addition of methylparaben is unnecessary in dental 
anesthetic cartridges14.
The results of the present study showed that the 
use of methylparaben in dental anesthetic solutions 
in Brazil must be re-evaluated considering either 
standardizing or abolishing it from these solutions. 
Furthermore, one solution contained in a glass 
cartridge presented the highest concentration 
of methylparaben among all the solutions 
evaluated. This fact is inexplicable considering the 
characteristics of the glass cartridge.
The quantities of methylparaben in the local 
anesthetic solutions evaluated in the present study 
largely varied among the manufacturers, since the 
use of this preservative is not controlled. Therefore, 
a regulatory legislation regarding this subject is 
clearly necessary. Despite the methylparaben 
concentrations observed in the present study were 
fairly below its lethal dose, this substance is one 
of the main causes of allergic reactions related to 
local anesthetics21.
There was a clear lack of standardization and 
information about methylparaben concentration on 
the drug insert package of the anesthetic solutions 
evaluated in the present study. This observation is 
in agreement with the results of a previous study1, 
which referred to the lack of information regarding 
methylparaben concentration in the drug insert 
package of other Brazilian drugs.
The present study showed that, except for 
prilocaine, the commercial brands using glass 
cartridges did not present methylparaben and 
are thus feasible alternatives to prevent allergic 
reactions to methylparaben in susceptible patients.
Agreeing with some authors11, the present study 
shows that further studies are needed to investigate 
the potential for reducing the concentration of 
preservatives in products such as local anesthetics.
CONCLUSIONS
The following conclusions can be stated: 
1. Methylparaben concentration varied among 
solutions from different manufacturers, and it was 
not indicated in the drug package inserts; 2. Since 
the presence of methylparaben in dental anesthetics 
is not regulated by the Brazilian National Health 
Surveillance Agency (ANVISA) and this substance 
could cause allergic reactions, it is important to alert 
dentists about its possible presence.
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